Pancreatic Reference Set Application: Kazufumi Honda-National Cancer Center (2014)
- Abbreviated Name
- Pancreatic Ref Set App: Honda (2014)
- Lead Investigator
- Honda, Kazufumi — Nippon Medical School
- Coordinating Investigator
- Zheng, Yingye — Fred Hutchinson Cancer Center
- Involved Investigators
Abstract
See objectives
Aims
To improve the survival rate of pancreatic cancer, non-invasive diagnostic methods that detect the disease in its early stage must be developed.
Analytic Method
The National Cancer Institute (NCI) will send the pancreatic cancer reference serum samples to the National Cancer Center, and the National Cancer Center (NCC) will then blindly measure the levels of apoAII isoforms in the reference samples. NCC will return the data obtained from the reference set, and the NCI will subsequently calculate sensitivity, specificity, and the AUC. In addition, the NCI will evaluate the clinical utility for early detection of pancreatic cancer
Comments
No comments available.
Outcome
The Pancreatic Cancer Reference Set includes a large cohort of early stage pancreatic cancer patients, recruited from 5 different institutions, and relevant control groups including healthy controls, subjects with chronic pancreatitis, and subjects with acute benign biliary obstruction. For various biomarkers measured using plasma or serum samples collected in the pancreatic cancer reference set, we conducted statistical analyses evaluating each biomarker’s classification performance, as characterized by the Receiver Operating Characteristic curve and the optimal sensitivity + specificity, to separate each control group from all pancreatic cancer patients, from stage-I and IIa pancreatic cancer patients, or from stage IIb pancreatic cancer patients. Classification performances were reported for individual biomarkers, and for regression models combining biomarkers and CA-19-9, with or without adjusting for individual’s age and diabetes status. Bootstrap confidence intervals were reported for biomarkers’ performance and their incremental values over CA19-9. Analysis reports were generated separately for each lab.
Secure Outcome
No secure outcome available.
Publications
Biomarkers
Data Collections
- No data collections available at this time for this protocol.
- Start Date
- Aug 26 2014
- Estimated Finish Date
- Aug 25 2015
- Finish Date
- Feb 18 2015
- Protocol ID
- 392
- Protocol Type
- Reference Set
- Fields of Research
-
- Proteomics
- Collaborative Group
- G.I. and Other Associated Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of pancreas
- Phased Status
- 1